[1]古再努尔·艾尔肯 古丽波斯旦·阿尤甫.MS患者泼尼松治疗前后外周血Th1、Th2、Th17、Treg、Tc1和Tc2淋巴细胞亚群变化[J].卒中与神经疾病杂志,2020,27(02):212-215.[doi:10.3969/j.issn.1007-0478.2020.02.016]
　Guzainuer Aierken,Gulibositan Ayoufu..The changes of Th1, Th2, Th17, Treg, Tc1 and Tc2 lymphocyte subsets in peripheral blood of MS patients before and after prednisone treatment[J].Stroke and Nervous Diseases,2020,27(02):212-215.[doi:10.3969/j.issn.1007-0478.2020.02.016]
点击复制

MS患者泼尼松治疗前后外周血Th1、Th2、Th17、Treg、Tc1和Tc2淋巴细胞亚群变化()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第27卷
期数:
2020年02期
页码:
212-215
栏目:
论 著
出版日期:
2020-03-15

文章信息/Info

Title:
The changes of Th1, Th2, Th17, Treg, Tc1 and Tc2 lymphocyte subsets in peripheral blood of MS patients before and after prednisone treatment
文章编号:
1007-0478(2020)02-0212-04
作者:
古再努尔·艾尔肯 古丽波斯旦·阿尤甫
844000 新疆喀什地区第一人民医院神经内二科
Author(s):
Guzainuer Aierken;  Gulibositan Ayoufu.
Department of Neurology, Kashi Prefecture First People’s Hospital, Kashi Prefecture 844000
关键词:
多发性硬化 泼尼松 T淋巴细胞 细胞因子
Keywords:
Multiple sclerosis Prednisone T lymphocyte Cytokines
分类号:
R744.5+1
DOI:
10.3969/j.issn.1007-0478.2020.02.016
文献标志码:
A
摘要:
目的 探讨多发性硬化(MS)患者泼尼松治疗前后外周血Tc1、Tc2、Treg、Th1、Th2及Th17淋巴细胞亚群变化。方法 选取本院45例MS患者(病例组)和35例同期于本院行常规体检的健康人员(对照组),比较病例组治疗前与对照组体检之日T淋巴细胞亚群和血浆细胞因子的水平,并比较病例组治疗前和泼尼松治疗后T淋巴细胞亚群和血浆细胞因子的水平。结果 病例组Tc1,Treg细胞百分率较对照组均明显降低,Th1,Th17细胞百分率较对照组显著增高,Th17/Treg细胞比例较对照组显著增高(P<0.01); 病例组与对照组Tc2,Th2细胞百分率及Th1/Th2细胞比例的比较均无明显差异(P>0.05); 与治疗前比较,病例组治疗1个月后Th1,Th17细胞百分率均明显降低,Treg,Tc1,Tc2细胞百分率均显著增高,Th17/Terg细胞比例显著下降(P<0.01); 病例组治疗1个月后Th2、Th1/Th2细胞比例与治疗前比较均无明显差异(P>0.05)。病例组白细胞介素-4(IL-4)和白细胞介素-10(IL-10)水平较对照组均显著下降,白细胞介素-17A(IL-17A)和 䥺SymbolgA@ -干扰素水平较对照组均明显增高(P<0.01); 与治疗前比较,病例组治疗1个月后IL-4和IL-10水平均明显增高,IL-17A和 䥺SymbolgA@ -干扰素水平显著下降(P<0.01)。结论 MS的发生可能与Treg下调、Th17上调密切相关,推测可能通过MS靶向提高Treg与降低Th17细胞百分率来维持Th17/Treg细胞比例的平衡。
Abstract:
ObjectiveTo study the changes of peripheral blood Tc1, Tc2, Treg, Th1, Th2 and Th17 lymphocyte subsets in patients with multiple sclerosis(MS)before and after prednisone treatment.Methods 45 MS patients(case group)and 35 healthy persons(control group)who underwent routine physical examination in our hospital at the same time were selected. The levels of T lymphocyte subsets and plasma cytokines were compared between the case group before treatment and the control group on the day of physical examination, and the levels of T lymphocyte subsets and plasma cytokines before treatment and after prednisone treatment were compared in the case group.Results The percentage of Tc1 and Treg cells in the case group was significantly lower than that in the control group, the percentage of Th1 and Th17 cells was significantly higher than that in the control group, and the percentage of Th17/Treg cells was significantly higher than that in the control group(P<0.01). There was no significant difference in the percentage of Tc2 cells, Th2 cells and Th1/Th2 cells between the case group and the control group(P>0.05). Compared with before treatment, the percentage of Th1 and Th17 cells in the case group decreased significantly after treatment, the percentage of Treg, Tc1 and Tc2 cells increased significantly, and the percentage of Th17/Terg cells decreased significantly(P<0.01). The percentage of Th2 and Th1/Th2 cells in the case group had no significant difference after treatment compared with that before treatment(P>0.05). The levels of interleukin-4(IL-4)and interleukin-10(IL-10)in the case group were significantly lower than those in the control group, and the levels of interleukin-17A(IL-17A)and interferon- 䥺SymbolgA@ were significantly higher than those in the control group(P<0.01). Compared with before treatment, the levels of IL-4 and IL-10 in the case group increased significantly after treatment, while the levels of IL-17A and IFN- 䥺SymbolgA@ decreased significantly(P<0.01).Conclusion The occurrence of MS might be closely related to Treg down-regulation and Th17 up-regulation. It was speculated that the proportion of Th17/Treg cells could be maintained by MS targeting to increase Treg and decrease Th17 cells in clinic.

参考文献/References:

[1] Jick SS,Li L,Gj F,et al.Epidemiology of multiple sclerosis:results from a large observational study in the UK[J].J Neurol,2015,262(9):2033-2041.
[2] Correale J,Gaitan MI,Ysrraelit MC,et al.Progressive multiple sclerosis: from pathogenic mechanisms to treatment[J].Brain,2017,140(3):527-546.
[3] Goodin DS.Glucocorticoid treatment of multiple sclerosis[J].Handb Clin Neurol,2014,122(1):455-464.
[4] 中国免疫学会神经免疫分会.中华医学会神经病学分会神经免疫学组.多发性硬化诊断和治疗中国专家共识(2018版)[J].中国神经免疫学和神经病学杂志,2018,25(6):387-394.
[5] Oh J,Vidal-Jordana A,Montalban X.Multiple sclerosis:clinical aspects[J].Curr Opin Neurol,2018,31(6):752-759.
[6] Bove R,Mchenry A,Hellwig K,et al.Multiple sclerosis in men: management considerations[J].J Neurol,2016,263(7):1263-1273.
[7] 王启荣,卢祖能,毛春,等.T细胞亚群与多发性硬化发病机制的关系[J].医学综述,2017,23(15):2918-2922.
[8] 李晓玲,张博,于春梅,等.Th17/Treg细胞在复发缓解型多发性硬化中的表达[J].中国神经免疫学和神经病学杂志,2015,22(3):153-155, 161.
[9] 傅增辉,姜岩,刘晶,等.多发性硬化患者Th17转录因子及相关细胞因子表达的研究[J].中国神经精神疾病杂志,2018,44(4):226-229.
[10] 李清学.多发性硬化与白细胞介素的关系[J].神经损伤与功能重建,2015,10(5):429-431.
[11] 任刚,李新毅,李玉峰,等.多发性硬化患者外周血辅助性T细胞17比率和血清辅助性T细胞17相关细胞因子水平的Meta分析[J].中华风湿病学杂志,2018,22(12):828-832.
[12] Sun JK,Zhang WH,Chen WX,et al.Effects of early enteral nutrition on Th17/Treg cells and IL-23/IL-17 in septic patients[J].World Journal of Gastroenterology,2019,25(22):2799-2808.
[13] Noval RM,Ta CL.Regulatory T cells in allergic diseases[J].J Allergy Clin Immunol,2016,138(3):639-652.
[14] Spence A,Klementowiczl JE,Bluestone JA,et al.Targeting Treg signaling for the treatment of autoimmune diseases[J].Curr Opin Immunol,2015,37(1):11-20.
[15] Bühler U,Fleischer V,Luessi F,et al.Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment[J].Mult Scler,2017,23(4):567-576.

备注/Memo

备注/Memo:
(2019-07-16收稿)
更新日期/Last Update: 2020-03-15